PC-12 Xenograft Model Service for Adrenal Cancer

The PC-12 xenograft model represents one of the most well-characterized and widely utilized preclinical platforms for evaluating therapeutic strategies against adrenal medullary tumors, particularly pheochromocytoma. At Alfa Cytology, a premier preclinical contract research organization specializing in oncology models, we provide comprehensive PC-12 xenograft model development and evaluation services tailored to accelerate your adrenal cancer drug discovery programs. Our experienced scientific team delivers reproducible, high-quality data through standardized protocols and state-of-the-art facilities, ensuring reliable preclinical insights for your therapeutic candidates.

Overview of PC-12 Xenograft Model for Adrenal Cancer

The PC-12 cell line was originally established in 1976 by Greene and Tischler from a transplantable pheochromocytoma arising in the adrenal medulla of an irradiated male rat (Rattus norvegicus, New England Deaconess Hospital strain). As a clonal line originating from chromaffin cells, PC-12 cells exhibit hallmark neuroendocrine characteristics including the synthesis, storage, and release of catecholamines --- specifically dopamine and norepinephrine --- while lacking epinephrine production. The cell line possesses a karyotype of 40 chromosomes (38 autosomes plus XY), expresses nerve growth factor (NGF) receptors, and demonstrates the unique capacity to differentiate into sympathetic neuron-like phenotypes upon NGF stimulation, making it a versatile model for both neurobiology and neuroendocrine tumor research. In preclinical oncology, PC-12 xenograft models have been extensively employed to evaluate the efficacy of radiotherapy, receptor tyrosine kinase inhibitors (including sunitinib and sorafenib), and novel targeted agents such as HSP90 inhibitors for pheochromocytoma treatment.

The PC-12 xenograft model is typically established through subcutaneous implantation of cultured PC-12 cells into immunodeficient mouse strains, most commonly nude (athymic) mice or NOD SCID mice. Following implantation, these cells form solid tumors that recapitulate key features of pheochromocytoma, including catecholamine secretion and neuroendocrine marker expression. The model offers several advantages for preclinical research: well-documented tumor growth kinetics, reproducible engraftment rates, compatibility with various therapeutic interventions, and established protocols for tumor monitoring and endpoint analysis. PC-12 xenografts have proven particularly valuable for testing radionuclide therapies, kinase inhibitors, and emerging molecular targeted agents, providing critical pharmacodynamic and efficacy data to support downstream drug development decisions.

Figure 1. Overview of the adrenal gland and the human and rodent in vitro cell lines available. (Luca, Edlira, et al., 2024)

Cell Line Information: PC-12

The following table summarizes the comprehensive characteristics of the PC-12 cell line, providing essential information for researchers considering this model for their preclinical studies:

Note: PC-12 cells do not synthesize epinephrine. The cells require collagen-coated culture vessels for optimal adherent growth and neurite differentiation. Early passages are recommended for reproducible xenograft formation.

Our Services

Alfa Cytology is a leading preclinical contract research organization dedicated to providing high-quality, customized in vivo tumor model services for cancer drug development. With extensive expertise in neuroendocrine tumor models, our team offers end-to-end PC-12 xenograft services --- from model establishment and quality validation to comprehensive efficacy studies and data reporting --- designed to meet the specific requirements of your research program and accelerate your path from discovery to preclinical candidate selection.

Workflow of PC-12 Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow for PC-12 xenograft model construction to ensure consistent and reproducible results. Each step is carefully optimized and documented, with rigorous quality checkpoints throughout the process.

Figure 2. Standardized workflow for PC-12 xenograft model construction at Alfa Cytology, encompassing cell culture preparation, harvesting, implantation, and tumor monitoring phases.

Step-by-Step Protocol

• Cell Culture Preparation: PC-12 cells are maintained in RPMI-1640 medium supplemented with 10% heat-inactivated horse serum, 5% fetal bovine serum, and 1% penicillin-streptomycin at 37 degrees C in a 5% CO2 humidified incubator. Cells are cultured on collagen-coated flasks and passaged at 70-80% confluence using routine subculture protocols. Only low-passage cells (below passage 20) are used to ensure optimal tumorigenicity and genetic stability.
• Cell Harvesting and Quality Control: Prior to implantation, cells are harvested during the exponential growth phase using gentle enzymatic dissociation. Cell viability is assessed by trypan blue exclusion (target viability greater than 95%), and cell density is adjusted to the appropriate concentration in sterile PBS or serum-free medium. Mycoplasma testing and sterility confirmation are performed for each batch.
• Animal Preparation: Immunodeficient mice (typically BALB/c nude or NOD SCID, 6-8 weeks old) are acclimatized for one week under standard laboratory conditions. Animals are examined for general health status prior to tumor cell implantation. All procedures are conducted in accordance with IACUC-approved protocols and international animal welfare guidelines.
• Subcutaneous Implantation: PC-12 cell suspension (typically 1-5 x 10^6 cells in 100-200 uL PBS/Matrigel mixture) is injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle. The injection site is monitored for any immediate adverse reactions. Alternatively, orthotopic implantation approaches can be employed based on specific study requirements.
• Tumor Monitoring and Measurement: Tumor growth is monitored twice weekly by digital caliper measurement. Tumor volume is calculated using the standard formula: Volume = (Length x Width^2) / 2. Animals are randomized into treatment groups when tumors reach the target volume (typically 100-200 mm cubed), ensuring comparable mean tumor sizes across all groups before therapeutic intervention.
• Study Execution and Endpoint Analysis: Following the study design, therapeutic agents are administered according to the predefined dosing schedule. Body weight and tumor measurements are recorded regularly. At study termination, tumors are excised, weighed, and processed for downstream analysis including histopathology, immunohistochemistry, gene expression analysis, and biomarker assessment as required.

Case Study-PC-12 Xenograft Model Development

Alfa Cytology has successfully developed and validated PC-12 xenograft models for multiple pharmaceutical and biotechnology clients engaged in neuroendocrine tumor drug discovery. In a representative engagement, our team established a robust PC-12 subcutaneous xenograft model demonstrating consistent tumor take rates and predictable growth kinetics suitable for efficacy evaluation of novel therapeutic candidates. The model supported comprehensive dose-response studies and provided clients with high-quality pharmacodynamic data, including tumor growth inhibition metrics, survival analysis, and correlative biomarker endpoints. Detailed study results, including tumor growth curves, endpoint tumor weight data, and histopathological findings, are available upon request through our scientific team.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise, operational excellence, and client-focused service delivery to provide industry-leading preclinical xenograft model solutions. Our PC-12 xenograft service is designed to generate reliable, reproducible data that advances your adrenal cancer therapeutic programs.

• Experienced Scientific Team --- Our PhD-level scientists bring extensive expertise in neuroendocrine tumor biology and xenograft model development, ensuring scientifically rigorous study design and execution.
• Standardized Protocols --- All PC-12 xenograft studies follow validated SOPs with stringent quality control at every stage, from cell line authentication to endpoint data collection.
• Comprehensive Service Portfolio --- We offer flexible service modules encompassing model establishment, efficacy studies, pharmacokinetic analysis, biomarker assessment, and histopathological evaluation.
• Real-Time Data Access --- Clients receive regular study updates and have access to raw data, tumor growth charts, and interim reports throughout the study duration.
• Regulatory Compliance --- All studies are conducted under IACUC-approved protocols in AAALAC-accredited facilities, with complete documentation to support IND-enabling packages.
• Competitive Timelines --- Our optimized workflows and dedicated project management ensure rapid study initiation and on-time delivery of final reports.
• Dedicated Project Management --- Each client is assigned a dedicated project manager who serves as a single point of contact and ensures transparent communication throughout the engagement.

Contact Us

Ready to advance your adrenal cancer research with our PC-12 xenograft model services? The team at Alfa Cytology is here to support your preclinical drug discovery programs with customized study designs and reliable data generation. Reach out to us today to discuss your project requirements, request a detailed service proposal, or schedule a consultation with our scientific experts. We look forward to partnering with you to accelerate your therapeutic development pipeline.

For research use only. Not intended for any clinical use.